Literature DB >> 11328274

Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.

D T Holyoake1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11328274     DOI： 10.1046/j.1365-2141.2001.02558.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Authors:  Fang Zheng; Huiyu Li; Kaiwei Liang; Yimei Du; Dongmei Guo; Shiang Huang
Journal:  Med Oncol       Date:  2011-12-10       Impact factor: 3.064

2.  miR-153 sensitized the K562 cells to As2O3-induced apoptosis.

Authors:  Li Liu; Renan Chen; Siyong Huang; Yanlan Wu; Guohui Li; Bei Zhang; Qiang Liu; Dandan Yin; Yingmin Liang
Journal:  Med Oncol       Date:  2011-01-26       Impact factor: 3.064

3.  Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.

Authors:  Ryoko Kuribara; Hiroaki Honda; Hirotaka Matsui; Tetsuharu Shinjyo; Takeshi Inukai; Kanji Sugita; Shinpei Nakazawa; Hisamaru Hirai; Keiya Ozawa; Toshiya Inaba
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

4.  The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.

Authors:  W M Liu; L A Stimson; S P Joel
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

5.  Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?

Authors:  T P de Almeida Filho; P A Maia Filho; Maritza Cavalcante Barbosa; Luana Letícia Alves Dutra; Marilena Facundo de Castro; Fernando Barroso Duarte; Acy Telles de Souza Quixadá; Romélia Pinheiro Gonçalves Lemes
Journal:  Hematol Transfus Cell Ther       Date:  2019-02-16

6.  Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia.

Authors:  Pengliang Xin; Wenqian Xu; Xiongpeng Zhu; Chuntuan Li; Yan Zheng; Tingjin Zheng; Wenzhao Cheng; Qunyi Peng
Journal:  Cancer Manag Res       Date:  2019-08-22       Impact factor: 3.989

7.  Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis.

Authors:  Chao-Sung Chang; Yi-Hsin Yang; Chien-Ning Hsu; Min-Ting Lin
Journal:  BMC Health Serv Res       Date:  2012-10-16       Impact factor: 2.655

8.  Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Authors:  Yueh-Lun Lee; Chih-Wei Chen; Fu-Hwa Liu; Yu-Wen Huang; Huei-Mei Huang
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

9.  MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.

Authors:  Shuit-Mun Wong; Fu-Hwa Liu; Yueh-Lun Lee; Huei-Mei Huang
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.